Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess performance of the resolute integrity rx coronary drug-eluting stent.Survey results from an interventional cardiologist in practice 7 years.In the past 12 months, the physician has used the resolute integrity stent 300 times.40 of the smallest (2.25 x 8 mm), 250 intermediate (2.25 x 12 mm to 4.00 x 34 mm) and 10 of the largest sizes (4.00 x 38 mm) of these stents were used.It was noted that the 5 devices were used in other non-coronary procedures to treat other arteries.The following complications adverse events/effects were encountered in the using the resolute integrity product over the last 12 months: four incomplete stent apposition events, all related to the procedure but not directly to the device itself.The following device complaints were encountered when using the resolute integrity product over the last 12 months: two events in which a burst balloon occurred.Both events reportedly had no clinical/patient impact.Two events in which detachment of component(s) (in vivo) occurred.Both events reportedly also had no clinical/patient impact.It was reported that the device did not perform as expected in terms of reaching the target lesion in 10 events because the lesion was unreachable due to calcification and strong kinking.It was also reported that in 5 events the device did not perform as expected in terms of dilation of the target lesion.It was stated that the lesion could not be sufficiently expanded due to massive calcification.
|